Frank Richard, MD, MBA is a seasoned medical doctor and has over 20 years of development experience in R&D. In his current role as VP Medical at Heidelberg Pharma AG, Germany, he is providing medical strategy and oversight for the preparation and conduct of phase I-III clinical studies using antibody-drug conjugates (ADCs). Additionally, he supports modelling &simulation activities to understand how to effectively use preclinical data from in vivo studies, mechanistic modeling, and bioanalysis to improve dose prediction and determine the optimal dose when introducing an ADC into clinical trials in various cancer indications.
Frank has been working in the past in Immune-Oncology, Immunology& Respiratory, Rare Hematology Diseases and Iron Metabolism across big pharma and biotech.
Frank holds a MD from Charité Medical University, Berlin, an MBA from University of Applied Sciences, Neu-Ulm, and is a board-certified Clinical Pharmacologist.
Additionally, he exerts an unique expertise and interest in Bayesian Statistics and machine learning in Pharma and Biotech.